proteins involved in both short patch and in long patch Base Excision Repair (BER) (A), Mismatch Repair (MMR) (B) and Nucleotide Excision Repair (NER) (C). BER: DNA glycosylases remove damaged bases giving rise to apurinic/apyrimidinic sites or DNA nicks. These AP-sites or nicks are sculpted to generate a DNA nick with 3'OH and 5'PO4 ends. In short patch BER, POLB and then XRCC1/LIG3 co-operate to insert an appropriate base and ligate the strand. In long patch BER, following clamping by PCNA either POLD or POLE (or POLQ) insert a number of complementary bases, 2-10 nucleotides, from the 3'OH end of the nick, creating a flap. The flap is removed by FEN1 and the nick ligated by LIG1. Both BER-SP and BER-LP are tied into the ATP/CHK2 reporting phosphorylation system. MMR: A mispair is recognized by a MutS heterodimer, causing MutL/PCNA recruitment and MutL nicks the newly synthesized strand next to the mismatch. In the Exo1-dependent subpathway, Exo1 excises the strand to a position past the mispair, which it is infilled and ligated by POLB/LIG3. In the absence of Exo1, POLD/E and FEN1 synthesize a complementary strand, past the mispair, the flap is excised and the LIG1 completes the repair. Canonical MMR MutSα/MutLα is in communication with ATM/CHK2 and ATR/CHK1 signaling systems, but this communication may be suppressed with MutSβ and with MutLβ and MutLγ. NER: XPC/R23B senses DNA helix-distorting lesions in global NER (GG-NER). In transcription-coupled repair (TC-NER) lesions are detected by RNA Pol blockage. The detection complexes communicate with ATR/ATM and attract the transcription factor IIH (TFIIH), a multicomponent complex composed of 10 subunits including CDK7. TFIIH opens a 10-20 nucleotide ssDNA bubble around the lesion using helicases XPB and XPD. XPA and RPA's stabilize the ssDNA and XPG makes an incision on the 3′ of the lesion and ERCC1/XPF makes a second incision 5′ of the lesion. The 3′ end is clamped by PCNA, allowing the gap to be filled by POLD/E and ligation by LIG1.
Supplementary Figure 3: MAOB and MGMT mRNA distribution in human tissues. Supplementary
shows the levels of MAOB and MGMT in human tissues. (A) shows the levels of mRNA of MAOB and MGMT, normalized to the liver, in potential off-target human tissues and show that liver has the highest level of MAOB and MGMT transcripts and that MAOB is undetectable in bone marrow, a tissue with low MGMT levels and the typical limiting tissue in alkylating agent chemotherapy. (B) presents the same data in the form of the MGMT/MAOB ratio. Tissues with high MAOB and low MGMT will be most sensitive to a PAM-OBG type prodrug and in humans, this would appear to be the brain, but human bone marrow appears to be the least sensitive to a MAOB-sensitive anti-MGMT prodrug. Supplementary Figure 4 : DNA repair pathway ratios as a function of GBM patient survival. Supplementary Figure 4 shows a heat map of mRNA levels of DNA repair enzymes, striated by GBM patient outcome. At the top of the heat map is shown the relative levels of MAOB. Shown are the main enzymes that drive the 9-1-1 pathway and the telomere extension pathway enzymes. The ratios of mRNA of key enzymes of different pathways were calculated and are presented. These ratios indicate which DNA repair pathways are up-/down-regulated in different survival cohorts. Figure 5 presents the survival curves of three groups of patients, with respect to MPG levels. (A) indicates that in the whole n = 110 patient population we find that the 79% of the patients with low levels of MPG have a poorer outcome than those with higher levels of MPG. The population was split into two subpopulations with either low or high XRCC1, linked to low and high BER-SP activity. In the n = 77 subpopulation of patients where we expect long patch BER to be favored over short patch BER, we find that HIGH MPG is a big risk factor and that the median survival between high and low MPG in this subpopulation is 7.3 months, (B). In the smaller population, n = 33, where short patch BER is likely to be highly active MGP we find that LOW MPG is a risk factor and that the median survival between the two groups is 6.4 months, (C).
Supplementary Figure 5: Patient survival with respect to MPG expression and stratified by XRCC1 (SP-BER) expression. Supplementary

